PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pazopanib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

25 hits

Bibliografisk träff 2012-11-08

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.

Dy GK, Infante JR, Eckhardt SG, Novello S, Ma WW, Jones SF, Huff A, Wang Q, Suttle AB, Ottesen LH, Adjei AA, Burris HA.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-012-9887-6

Bibliografisk träff 2012-11-01

Pazopanib: in advanced soft tissue sarcoma.

Deeks ED.

Drugs · journal article · DOI 10.2165/11209950-000000000-00000

Bibliografisk träff 2012-10-22

Reversible posterior leukoencephalopathy syndrome induced by pazopanib.

Chelis L, Souftas V, Amarantidis K, Xenidis N, Chamalidou E, Dimopoulos P, Michailidis P, Christakidis E, Prassopoulos P, Kakolyris S.

BMC Cancer · journal article; case reports; case-report · DOI 10.1186/1471-2407-12-489

Bibliografisk träff 2012-10-11

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.

Plummer R, Madi A, Jeffels M, Richly H, Nokay B, Rubin S, Ball HA, Weller S, Botbyl J, Gibson DM, Scheulen ME.

Cancer Chemother Pharmacol · comparative study; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s00280-012-1982-z

Bibliografisk träff 2012-10-06

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.

de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s10637-012-9885-8

Bibliografisk träff 2012-08-10

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.

Sparidans RW, Ahmed TT, Muilwijk EW, Welzen ME, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci · journal article · DOI 10.1016/j.jchromb.2012.08.004

Bibliografisk träff 2012-08-04

Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.

Zivi A, Cerbone L, Recine F, Sternberg CN.

Expert Opin Drug Saf · comparative study; review; journal article · DOI 10.1517/14740338.2012.712108

Bibliografisk träff 2012-07-04

An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J, Stockdale A, Rashid S, Nathan P, Chowdury S.

Eur J Cancer · clinical trial, phase ii; comparative study; journal article · DOI 10.1016/j.ejca.2012.05.022

Bibliografisk träff 2012-07-02

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV.

Lancet Oncol · research support, non-u.s. gov't; journal article · DOI 10.1016/s1470-2045(12)70241-3

Bibliografisk träff 2012-07-01

[Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].

Gennigens C, Jerusalem G.

Rev Med Liege · journal article

Bibliografisk träff 2012-06-26

Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases.

Winum JY, Maresca A, Carta F, Scozzafava A, Supuran CT.

Chem Commun (Camb) · research support, non-u.s. gov't; journal article · DOI 10.1039/c2cc33415a

Bibliografisk träff 2012-06-25

Concise drug review: pazopanib and axitinib.

van Geel RM, Beijnen JH, Schellens JH.

Oncologist · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1634/theoncologist.2012-0055

Bibliografisk träff 2012-06-09

Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.

Minocha M, Khurana V, Qin B, Pal D, Mitra AK.

Int J Pharm · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ijpharm.2012.05.038

Bibliografisk träff 2012-06-07

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.

Burris HA, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, Levinson KT, Lindquist D, Gainer SD, Dar MM, Suttle AB, Ball HA, Tan AR.

Mol Cancer Ther · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1535-7163.mct-11-0997

Bibliografisk träff 2012-06-01

Pazopanib in the treatment of soft tissue sarcoma.

Schöffski P.

Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/era.12.41

Bibliografisk träff 2012-05-16

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group.

Lancet · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(12)60651-5

Bibliografisk träff 2012-02-22

A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.

Hosaka S, Horiuchi K, Yoda M, Nakayama R, Tohmonda T, Susa M, Nakamura M, Chiba K, Toyama Y, Morioka H.

J Orthop Res · research support, non-u.s. gov't; journal article · DOI 10.1002/jor.22091

Bibliografisk träff 2012-02-16

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther · review; journal article · DOI 10.1016/j.clinthera.2012.01.014

Bibliografisk träff 2012-01-10

Pazopanib for the treatment of breast cancer.

Amiri-Kordestani L, Tan AR, Swain SM.

Expert Opin Investig Drugs · review; journal article; research support, n.i.h., extramural · DOI 10.1517/13543784.2012.652304

Bibliografisk träff 2012-01-01

A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.

Robak P, Robak T.

Curr Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.2174/092986712803833371

Bibliografisk träff 2011-12-20

Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.

Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer · research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/pbc.24016

Bibliografisk träff 2011-12-01

Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.

Kasper B, Hohenberger P.

Future Oncol · journal article · DOI 10.2217/fon.11.116

Bibliografisk träff 2011-08-03

A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.

Heath EI, Forman K, Malburg L, Gainer S, Suttle AB, Adams L, Ball H, LoRusso P.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s10637-011-9725-2

Bibliografisk träff 2011-04-01

Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.

Melichar B, Studentová H, Zezulová M.

J BUON · research support, non-u.s. gov't; review; journal article

Bibliografisk träff 2011-03-11

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.

Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME.

Invest New Drugs · meta-analysis; research support, non-u.s. gov't; systematic review; journal article · DOI 10.1007/s10637-011-9652-2